Carbapenem Therapy for Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Escherichia coli or Klebsiella pneumoniae: Implications of Ertapenem Susceptibility
Carbapenem Therapy for Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Escherichia coli or Klebsiella pneumoniae: Implications of Ertapenem Susceptibility
复制标题
DOI：
10.1128/aac.06301-11
复制
发表时间：
2012-06-01
影响因子：
4.9
通讯作者：
Ko, Wen-Chien
中科院分区：
文献类型：
--
作者：
Lee, Nan-Yao;Lee, Ching-Chi;Ko, Wen-Chien
在台湾的两个医学中心进行了一项回顾性研究，以评估因产超广谱β-内酰胺酶(ESBL)细菌引起的菌血症而使用碳青霉烯类药物治疗的患者的临床特征、结果和死亡危险因素。共鉴定了251例由产超广谱β-内酰胺酶的大肠埃希菌和肺炎克雷伯菌引起的碳青霉烯类治疗的菌血症患者。在这些产超广谱β-内酰胺酶的菌株中，对埃他培南(MICs)的敏感率
A retrospective study was conducted at two medical centers in Taiwan to evaluate the clinical characteristics, outcomes, and risk factors for mortality among patients treated with a carbapenem for bacteremia caused by extended-spectrum-beta-lactamase (ESBL)-producing organisms. A total of 251 patients with bacteremia caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae isolates treated by a carbapenem were identified. Among these ESBL-producing isolates, rates of susceptibility to ertapenem (MICs